Clinical Trial

Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke

Study acronym: Ischemic strok
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-02.
Trial Details
NCT Number NCT07260760
Lead Sponsor Qianfoshan Hospital
Conditions Acute Ischemic Stroke
Enrollment 600 participants
Start Date 2026-01-20
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-15